A Phase 1 interventional study of Admilparant in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the effect of food on the drug levels of Admilparant
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Admilparant
Drug: Admilparant
Drug: Admilparant
Drug: Admilparant
Specified dose on specified days
Maximum observed plasma concentration (Cmax)
Time frame: Up to 13 days
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Time frame: Up to 13 days
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Time frame: Up to 13 days
Time of maximum observed plasma concentration (Tmax)
Time frame: Up to 13 days
Terminal half-life (T-HALF)
Time frame: Up to 13 days
Apparent total body clearance (CLT/F)
Time frame: Up to 13 days
Apparent volume of distribution (Vz/F)
Time frame: Up to 13 days
Number of participants with adverse events (AEs)
Time frame: Up to 13 days
Number of participants with a change in clinical laboratory values
Time frame: Up to 13 days
Number of participants with a change in vital sign measurements
Time frame: Up to 13 days
Number of participants with a change in physical examination results
Time frame: Up to 13 days
Number of participants with a change in 12-lead electrocardiogram (ECG) results
Time frame: Up to 13 days
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · www.bms.com
Ran from Nov 2025 to primary completion in Jan 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Admilparant